Solid Biosciences Inc.
- Last sale
- Nov 12, 2026 · -7.89%
- Market cap
- $781.83M
- 111.61M shares
- Filings
- 739
FY 2022−40.6% FY22 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−25.3% FY25 yoy
- $781.83M
- —
- —
- 2.3×
- -20.14%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2022 | 2022-12-31 | $8,094,000 | reported | |
| FY 2021 | 2021-12-31 | $13,620,000 | reported | |
| FY 2020 | 2020-12-31 | $0 | reported | |
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 | reported | |
| FY 2017 | 2017-12-31 | $0 | reported | |
| FY 2016 | 2016-12-31 | $0 | reported |
Biological products, except diagnostic substances
Solid Biosciences Inc. is the 50th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
IMTXImmatics N.V.———$871.5MMGTXMeiraGTx Holdings plc$81.4M144.6%140.3%$858.1MGLUEMonte Rosa Therapeutics, Inc.$123.7M63.5%31.2%$793.0M
SLDBSolid Biosciences Inc. (this company)———$781.8M
AURAAura Biosciences, Inc.———$740.5MATTOAttovia Therapeutics, Inc.———$723.6MPRMEPrime Medicine, Inc.$4.6M55.3%4,342.4%$705.9MFDMT4D Molecular Therapeutics, Inc.$85.2M230,194.6%164.4%$682.1MCGEMCullinan Therapeutics, Inc.———$661.5MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Solid Biosciences Inc. · CIK 1707502 · Engraved from SEC EDGAR